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Objectives: To assess the cost-effectiveness (CE) of switching from NPH insulin 
± oral glucose-lowering drugs (OGLDs) to insulin detemir ± OGLDs in people with 
type 2 diabetes (T2DM) in countries in different economic circumstances based on 
observational data gathered in routine clinical practice. MethOds: The A1chieve
® 
study assessed safety and outcomes over 24 weeks in 66,726 people with T2DM 
starting insulin analog therapy. Most people (96%) stated better glycemic control 
as reason to switching therapy, with 31% also stating hypoglycemia problems as 
a further reason. The CE analyses included data for people switching to detemir 
in South Korea (n= 90) and in seven Arabian Gulf countries (n= 124). Data were col-
lected on clinical effectiveness and adverse events, and health-related quality of 
life using the EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model 
with 1 and 30 year time horizons, with South Korea and Saudi Arabia country-
specific costs for complications and therapies and background mortality rates. CE 
was measured by comparing outcomes at study-end with outcomes at pre-study. 
Incremental cost-effectiveness ratios (ICERs) are expressed as cost per QALY in 
local currencies, USD and in fractions of local GDP per capita. CE was pre-defined 
using the WHO definition of < 3 times GDP per capita. Results: 1-year ICERs were: 
South Korea (KWR 3,236,798; USD 2,980; GDP 0.13), and Saudi Arabia (SAR 27,221; 
USD 7,258; GDP 0.36). 30-year ICERs were: South Korea (KWR 872,589; USD 803; 
GDP 0.04), and Saudi Arabia (SAR 6,349; USD 1,693; GDP 0.08). Sensitivity analyses 
covering cost of self-monitoring, deterioration of glucose control with time, and 
other time horizons showed the results to be robust. cOnclusiOns: Switching 
from NPH±OGLDs to detemir±OGLDs in people with T2DM as performed in the 
A1chieve
® study was found to be cost-effective in both country settings at 1 and 
30 year time horizons.
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Objectives: To assess the cost-effectiveness (CE) of switching from insulin glargine ± 
oral glucose-lowering drugs (OGLDs) to insulin detemir ± OGLDs in people with type 2 
diabetes (T2DM) in Saudi Arabia, South Korea and Algeria based on observational data 
gathered in routine clinical practice. MethOds: The A1chieve
®study assessed safety 
and outcomes over 24 weeks in 66,726 people with T2DM starting insulin analog ther-
apy. The CE analyses included people switching to detemir in Saudi Arabia (n= 102), 
South Korea (n= 82) and in 3 North-West African countries (n= 94). Data were collected 
on clinical effectiveness and adverse events, and health-related quality of life using 
the EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 
30 year time horizons, with Saudi Arabia, South Korea and Algeria country-specific 
costs for complications and therapies and background mortality rates. Incremental 
cost-effectiveness ratios (ICERs) are expressed as cost per QALY in local currencies, 
USD and in fractions of local GDP per capita. CE was pre-defined using the WHO defi-
nition of < 3 times GDP per capita. Results: The switch was found to be less costly 
and have better outcomes in South Korea after 30 years and in Saudi Arabia at both 
time horizons. 1-year ICERs were: Saudi Arabia (SAR -5,849; USD -1,559; GDP -0.08), 
South Korea (KWR 296,842; USD 273; GDP 0.01), and Algeria (DZD 267,771; USD 3,363; 
GDP 0.80). 30-year ICERs were: Saudi Arabia (SAR -14,839; USD -3,957; GDP -0.19), South 
Korea (KWR -1,133,202; USD -1,043; GDP -0.05), and Algeria (DZD 226,818; USD 2,849; 
GDP 0.68). Sensitivity analyses on the 30 year time horizon showed the findings to be 
robust. cOnclusiOns: Switching from glargine±OGLDs to detemir±OGLDs in T2DM 
as performed in the A1chieve
® study was found to be cost-effective across all country 
settings at 1 and 30 year time horizons.
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ObjectivOs: Estimar y caracterizar el impacto de la enfermedad sobre la productivi-
dad laboral de personas con diabetes (DM) en Argentina. MetOdOlOgíAs: Estudio 
descriptivo observacional relevando información mediante el cuestionario WPAI-GH 
(Work productivity and activity impairment - General Health version) en personas 
adultas (18 a 75 años) con DM, que concurrieron a su consulta habitual a dos centros 
asistenciales de La Plata. Los encuestados también respondieron sobre aspectos 
socioeconómicos y complicaciones de su enfermedad. La pérdida de productividad 
se estimó por el método del capital humano. Los resultados se presentan como 
media ± desvío estándar (DS) o proporciones. Para las comparaciones se utilizaron 
los test t de student, Kruskal-Wallis y Chi cuadrado, según correspondiera. Se con-
sideró significativo p< 0,05. ResultAdOs: Aceptaron participar en el estudio 73 
personas con DM; 54,8% hombres con edad de 57 ± 15 años. El 42,5% poseía estudios 
superiores (nivel terciario o universitario completo). El 60,3% trabajaba, 6.4% estaba 
desempleado y el 33,3% inactivo (jubilado, pensionado). El tiempo promedio de tra-
bajo fue de 43 ± 17 horas/semana y el 38% faltó/retiró de su trabajo por su enferme-
dad. El tiempo de trabajo perdido por ausentismo fue 9.1%, y por disminución de 
la productividad el 22%. La diabetes también disminuyó un 25% la capacidad para 
realizar actividades regulares diarias, afectando más a mujeres que a hombres (30 
y 20,3%, respectivamente). La pérdida de productividad monetaria por ausentismo 
CANA doses and SITA significantly reduced systolic blood pressure (CANA 100mg: 
5.36 mmHg; CANA 300mg: 6.58 mmHg; SITA 3.34 mmHg), however, only CANA sig-
nificantly reduced body weight (CANA 100mg: 2.5%; CANA 300mg: 2.9%) versus 
placebo. The objective of this study was to simulate the health outcomes and associ-
ated costs attributable to using CANA versus SITA in Mexico. MethOds: Forty-year 
outcomes associated with adding CANA 100mg or CANA 300mg versus SITA to 
MET were simulated using ECHO (Economic and Health Outcomes)-T2DM, a vali-
dated micro-simulation model. Treatment effects and patient characteristics were 
sourced from the trial. Simulated treatment was intensified when HbA1cexceeded 
7.5% by adding basal insulin, and subsequently prandial insulin. Disutilities associ-
ated with micro- and macro-vascular events were obtained from the literature and 
costs were adapted to the Mexican setting. Results: Using CANA 300mg versus 
SITA was projected to reduce relative risks for key events (e.g. myocardial infarction 
10.2%; congestive heart failure 6.6%; macroalbuminuria 6.6%; microalbuminuria 
6.2%), improve QALYs (0.046), and result in lower costs per patient ($1927MXN). 
Simulation results of CANA 100mg versus SITA were generally similar, albeit esti-
mates of reductions in relative risks, QALY gains and associated costs differences 
were smaller. cOnclusiOns: These simulations suggest that using CANA versus 
SITA as an add-on to MET could result in improved outcomes and reduced costs 
in Mexico.
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Objectives: Compare expected costs and health-outcomes in patients with 
Diabetes Mellitus Type 2 (DMT2) in the Public Sector in Mexico treated with 
glargine or 25%-insulin lispro, 75%-insulin lispro protamine suspension 
(LM25). MethOds: This analysis included a hypothetical cohort of insulin-naïve 
patients with T2DM, aged 30–80, years, with A1C> 7.0% taking antihyperglycemic 
drugs for 90 days. Effectiveness measures included; (1) Percentage of patients with 
A1C< 7.0% levels at 24 weeks, (2) frequency and type of micro and macrovascular 
complications (MMVC) and (3) hypoglycemic events per 1000 patients consider-
ing one-year timeframe. Costs evaluated were: 1) acquisition costs; 2) cost of 
hypoglycemic events; and 3) MMVC. Efficacy measures and mean-daily-dose was 
obtained from DURABLE, parallel, open-label and randomized study comparing 
directly LM25 and Glargine. Incidences of MMVC were estimated using data from 
UKPDS study group and data from Meta-analysis by Quayum following a similar 
process outlined by Grima. Acquisition costs were derived from the transparency 
portal of the Mexican Social Security Institute. Healthcare services utilization 
from hypoglycemic episodes were calculated according to international published 
literature and IMSS Unit Costs updated to 2013 following IMSS methodology, while 
other associated expenses with MMVC complications come from Mexican reports 
and Diagnostic Related Groups (DRG) published by IMSS this data was updated to 
January 2013 using the Bank of Mexico inflation calculator. Costs are expressed 
in 2013 USD (1USD= $12.70MXN) Results: All results consider 1000 patients 
treated in a 1-yeat timeframe. Acquisition costs for LM25 were lower compared 
to glargine ($291,395 vs $383,521, 24% lower), although costs per hypoglycemia 
events were higher for LM25 ($12,242 vs. $3,673). Direct medical costs for MMVC 
were higher for Glargine ($668,027 vs. $754,435) Total medical costs were higher 
for glargine compared to LM25 ($971,663 vs. 1,141,628). cOnclusiOns: Results 
of the present study suggest that compared with LM25, health care costs are 
significantly higher for glargine.
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Objectives: To estimate the health economic impact of Sensor-Augmented 
Insulin Pump (SAP) Therapy among Insulin-Dependent Diabetes Mellitus (IDDM) 
patients in Colombia. MethOds: The Core Diabetes Model (CDM) is highly vali-
dated, computer simulation model to determine the long-term health outcomes 
and economic consequences of diabetes interventions. A recent real life clinical 
study in Colombia evaluating 217 IDDM patients (average baseline HbA1c of 8.97%, 
mean age 34 years, and average diabetes duration of 14 years) who initiated SAP 
therapy showed that SAP therapy led to a reduction of -1.47% HbA1c as well as a 
significant reduction in severe hypoglycaemic events. The impact of the reduction 
in the fear of hypoglycaemic events on quality of life was also included. Results: 
Life expectancy of patients with SAP was increased by 3.51 years and diabetes 
related complications were delayed on average by 1.74 years. The Incremental-
Cost-Effectiveness-Ratio (ICER) for SAP was $44,889,916COP ($24,939USD) per 
Quality-Adjusted-Life-Year gained based on direct costs only. SAP related ther-
apy costs were partially offset by the savings due to the reduction in long-term 
complications, including proliferative diabetic retinopathy (PDR), Severe Vision 
Loss (SVL), End Stage Renal Disease (ESRD), and Amputations (AMP). The relative 
reduction in incidence of these complications (PDR 42%, SVL 20%, ESRD 46%, AMP 
12%) as well as the average delay in their onset (4.9 years, 4.0 years, 3.8 years, 3.7 
years, respectively) due to SAP therapy is profound. When including indirect costs, 
SAP demonstrated an even lower ICER. Extensive sensitivity analyses showed the 
robustness of the results. cOnclusiOns: Using a payer’s perspective, our analysis 
showed that SAP is cost-effective over a lifetime horizon in IDDM patients in the 
Colombian setting (using a WTP threshold of $60,771,600COP [3x GDP]) and can 
lead to an increase in life expectancy. When using a societal perspective, SAP was 
even more cost-effective.
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was reduced to 22 items. Exploratory and confirmatory factor analysis identified 21 
items contributing to 3 hypoglycemia domains (Symptoms [8 items], Compensatory 
Behaviors [7 items], Worry [6 items]) and a single-item of global symptom awareness. 
HPQ domains had high internal consistency reliability (Cronbach’s alpha= 0.78-0.92). 
Construct validity was demonstrated by significant correlations between HPQ scores 
with HRQoL, treatment satisfaction, and health status. HPQ also demonstrated abil-
ity to discriminate between known groups. Compensatory behaviors and symptom 
awareness were higher for patients with a recent low blood sugar event (p< 0.001) 
and high symptom awareness corresponded to less concern about experiencing 
symptoms of low blood sugar and worry (p< 0.05). cOnclusiOns: These results 
provide preliminary evidence that HPQ is reliable and valid for assessing the experi-
ence and impact of hypoglycemia on T2DM patients.
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Objectives: To test the reliability and validity and of newly translated Hindi version 
of DQOL-M instrument in Indian type 2 diabetic populations. MethOds: Backward 
and forward translation was carried out and intermediate version was compared 
with original instrument to check the linguistic equivalence. After pilot testing the 
final Hindi version of DQOL-M was administered to 250 patients with type 2 dia-
betes twice at the interval of four weeks. Psychometric parameters like treatment 
satisfaction, Impact of treatment, worries of social vocational issues of diabetes 
were assessed. Cronbach alpha for total score was calculated to study the reliability 
of instrument. Results: Internal consistency was assessed using Cronbach alpha 
and value of 0.86 was gained for the summary score. Cronbach alpha for treatment 
satisfaction was found to be 0.77, for Impact of treatment it was 0.73 and for wor-
ries of social vocational issues score of 0.83 was gained. No significant difference 
was observed in test-retest analysis. Pearson correlations were assessed for all the 
four subscales and were found to be significant. cOnclusiOns: This modified 
and final translated version of instrument confirms the linguistic validity of the 
questionnaire for the Hindi language and evaluates the psychometric properties 
of the questionnaire for psychometric validation. Indian Hindi version of DQOL-M 
is valid and reliable instrument for measuring HRQOL of diabetic type 2 patients.
DiaBeteS/enDoCrine DiSorDerS – health Care use & Policy Studies
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Objectives: Metabolic agents have the highest expense (130 million Euros per year 
in the Valencian Community) among the top five therapeutic categories of drugs 
for adults aged 18 and over. Treatment of Diabetes Mellitus (DM) is the main cause 
of this. Moreover, diabetes is a chronic illness that requires continuous medical 
care and patient self-management education to prevent acute complications and 
to reduce the risk of long-term complications. Clinical Risk Groups (CRGs) are a 
tool claimed as valid for diabetes patient management. In this context we use this 
methodology to conduct a pharmaceutical cost analysis of diabetes in an Eastern 
Spanish region where the prevalence reaches approximately 8 %. MethOds: A 
database of 5,200,000 subjects was used to analyse the prevalence of patients with 
DM, comorbidity and complications. The patients with DM diagnoses were clas-
sified into CRGs to know their severity levels and pharmaceutical cost was also 
assigned. A multivariable statistical analysis was performed to evaluate the cor-
relation and level of explanation between CRGs’ severity level and pharmaceutical 
expenditure. Results: Identified 300,698 patients with DM type 2 for a prevalence 
of 7.85% in men and 6.77% in women being the 13.2% and 7,98% in unders 50 years 
old, respectively. The 69,1% treated with orals hypoglycemics being combied therapy 
in over 75% of these. The use cosumption ratio glucometer strip, increaes with 
disease progression. It Was posible to identify the presence of complicactions in 
patiens analysed. A high correlation between pharmaceutical costs and CRG severity 
level was found. Comorbidity is a predictor for adjusting the risk of pharmaceuti-
cal expenditure. cOnclusiOns: The model obtained could be a useful tool for 
managing pharmaceutical budget policies and patient management. The use of 
this measurement technique is useful for monitoring the health medical expense.
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Objectives: To assess the improvement in knowledge and attitude of Pharmacy stu-
dent towards diabetes by implementing one week education program. MethOds: 
Study was conducted between January 7, 2013 to January 11, 2013 which engaged 
pharmacy students comprising two groups: experimental and control groups. 
Lectures and visual presentations on diabetic education and practice were con-
ducted. Three surveys were performed on two group’s i.e. non intervened control, 
non- intervened experimental and intervened experimental surveys. Questionnaire 
was used as survey tool. Results: Mean score on knowledge about diabetes was 
increased from 68.81% to 88.90% after educational intervention while that of control 
group was 74.75%. General knowledge of diabetes was increased from 66.37% to 
89.90% while that of control was 69.28%. Risk factors knowledge was increased from 
61.05% to 90.20% while that of control was 70.20%. Symptoms knowledge increased 
debido a la DM se estimó en $21,516 ± 8062 año/persona. cOnclusiOnes: La DM 
afecta significativamente la productividad laboral en nuestro medio.
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CoSto DeL automonitoreo gLuCémiCo en PaCienteS en tratamiento 
ComBinaDo oraL y Con inSuLina en argentina
Elgart J., Gonzalez L., Gagliardino J.J., Rucci E.
CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, 
Argentina, Buenos Aires, Argentina
ObjectivOs: Aunque el automonitoreo glucémico (AMG) es una herramienta útil 
para optimizar el control de la diabetes, no existe en Argentina evidencia de su uso 
e impacto económico. Este estudio trata de estimar en Argentina, el número de tiras 
reactivas (TR) para AMG utilizadas en el Sistema de la Seguridad Social (SSS) y su 
impacto en el costo total de la prescripción terapéutica, en la transición de terapia 
combinada de antidiabéticos orales (ADO) al agregado de insulina. MetOdOlOgíAs: 
Estudio observacional retrospectivo, utilizando registros de una organización del SSS 
(OSPERYH, consumo de TR de 681 afiliados durante 2012) y de otras dos entidades 
de la SSS, a través de 8.115 recetas anónimas de medicamentos y TR prescriptas 
en el período Febrero-Abril 2012 y registradas por el Colegio Farmacéutico de la 
Provincia de Buenos Aires (COLFARMA). Los resultados representan la media ± des-
vío estándar (DS) o proporciones. Evaluación estadística: utilizamos los test t de 
student, Kruskal-Wallis y Chi cuadrado, según correspondiera. Se consideraron sig-
nificativas diferencias con p< 0,05. ResultAdOs: OSPERYH: las TR fueron provistas 
bajo sistema de auditoría que incluye educación diabetológica, tipo de tratamiento y 
grado de control metabólico. Los tipos de tratamiento afectaron significativamente 
el consumo mensual de TR: combinación ADOs 25±12 vs. , ADO+insulina 36±15. El 
costo total combinación ADOs fué $456 vs.ADO+insulina $669 y las TR represen-
taron el 42% y 32% del costo total, respectivamente. COLFARMA: también el tipo de 
terapia afectó significativamente el consumo mensual de TR pero con valores tres 
veces superiores: combinación ADOs 75±47 vs. ADO+insulina 89±63. El costo total 
combinación ADOs fue $711 vs.ADO+insulina $983, y las TR representaron el 63% y 
54% del costo total, respectivamente. cOnclusiOnes: El consumo de TR para AMG 
aumenta en función de la incorporación de insulina al tratamiento y auditorías 
como la descripta optimizan su consumo e impacto económico.
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reLaCión DeL ÍnDiCe De maSa CorPoraL y gaSto en meDiCamentoS en 
PerSonaS Con DiaBeteS en argentina
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Argentina, Buenos Aires, Argentina
ObjectivOs: Evaluar la relación entre el Indice de Masa Corporal (IMC) y el gasto 
en medicamentos de personas con Diabetes (DM) en Argentina. MetOdOlOgíAs: 
Estudio descriptivo observacional relevando el IMC y el consumo de medicamentos 
de la Base QUALIDIAB. El gasto mensual en medicamentos se determinó mediante 
técnicas de microcosteo, considerándose el precio promedio de las presentaciones 
disponibles en el mercado, sin ajustes. Los valores se expresaron en pesos argen-
tinos (Diciembre 2012). Las personas se estratificaron según IMC de acuerdo a la 
clasificación de la OMS (Normal: ≥ 18,5 y < 25; Sobrepeso: ≥ 25 y < 30; Obesidad: 
IMC≥ 30). Los resultados se expresaron como media ± desvío estándar (DS). Para las 
comparaciones se utilizaron los test t de student, ANOVA y Kruskal-Wallis, según 
correspondiera. Coeficientes de correlación de Pearson (r) se utilizaron para evaluar 
el grado de asociación. Se consideraron significativos p< 0,05. ResultAdOs: Se anal-
izaron 1134 registros, edad 63 ± 12 años, 55,4% mujeres. El gasto promedio mensual 
en medicamentos fue de $ 975, el gasto en medicamentos para la DM fue $779, 
para la Hipertensión $ 241 y para la Dislipemia $ 128. El gasto en medicamentos 
aumentó en función del IMC: Normal: $782; Sobrepeso: $936 y Obesidad: $1149. 
El gasto fue significativamente mayor en Hombres ($1045 vs. $919). El gasto total 
de medicamentos se correlacionó significativamente con IMC (r: 0,164), al igual 
que el correspondiente a medicamentos antihipertensivos (r: 0,113) y los utiliza-
dos para controlar la hiperglucemia (r: 0,079). cOnclusiOnes: En pacientes con 
DM en Argentina, el IMC se asocia positivamente con el gasto en medicamentos. 
Estrategias terapéuticas que disminuyan efectivamente el IMC generarían beneficios 
tanto médicos como económicos.
DiaBeteS/enDoCrine DiSorDerS – Patient-reported outcomes & Patient 
Preference Studies
PDB21
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Objectives: The Hypoglycemia Perspectives Questionnaire (HPQ) was developed 
with clinician and patient input to assess symptoms, behaviors, and impact of 
hypoglycemia on diabetic patients. MethOds: The HPQ was administered to adult 
patients with type 2 diabetes mellitus (T2DM) on antidiabetic treatment as part 
of a cross-sectional, epidemiological study evaluating hypoglycemia and health-
related quality of life (HRQoL) in Cyprus. Demographic and clinical data were col-
lected. Patients also completed the Audit of Diabetes Dependent Quality of Life 
(ADDQoL-19), treatment satisfaction questionnaire, and EuroQol-5 Dimensions (EQ-
5D). The original HPQ consisted of 45 items rating current status or behavior related 
to hypoglycemia on an 11-point numeric rating scale (NRS) and 7 additional descrip-
tive hypoglycemia event frequency items. Analyses included examination of HPQ 
item performance, item reduction, and factor structure. Measurement properties 
(reliability, construct validity, known-groups validity) of the final HPQ were evalu-
ated. Results: A total of 500 T2DM patients completed the HPQ with a mean age 
of 61±10 years; 32.6% women. Based on item evaluation, the original HPQ item pool 
